Avalo Therapeutics to join Russell 2000, 3000 indexes (AVTX:NASDAQ)
Avalo Therapeutics (AVTX) joins the Russell 2000 & Russell 3000 effective June 26, 2026.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Avalo Therapeutics (AVTX) joins the Russell 2000 & Russell 3000 effective June 26, 2026.
Avalo Therapeutics to join Russell 2000, 3000 indexes (AVTX:NASDAQ) | Seeking Alpha
Copy Link
Save
Play
(
<1min
)
Comments
Avalo Therapeutics (
AVTX
) is set to join the small-cap Russell 2000 Index and the broad-market Russell 3000 Index.
TheÂ
addition
is effective after the close of U.S. equity markets on June 26, 2026.
More on Avalo Therapeutics
Avalo Therapeutics: Sell-Off Could Continue If Overall Market Deteriorates Further
Avalo Therapeutics: Abdakibart Delivers Breakout Phase 2 HS Data
Avalo Therapeutics GAAP EPS of -$0.98 beats by $0.05
Avalo Therapeutics prices $375M public offering; shares jump
Seeking Alphaâs Quant Rating on Avalo Therapeutics
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Entering text into the input field will update the search result below
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Solana Company Stakes 500K SOL on Tokyo Cluster, Validator Rewards Expected by Q3 2026
A Solana infrastructure firm has pledged 500,000 SOL to support its Tokyo cluster, with first validator rewards projected for Q3 2026, signaling confidence in network decentralization and Asian expansion.
Barfresh outlines $23M-$26M FY2026 revenue outlook while targeting partial commissioning of Defiance plant by end of 2026 (NASDAQ:BRFH)
Barfresh (BRFH) Q2 2026 earnings call recap: Arps-driven revenue growth, production ramp issues, and revised FY2026 guidance.
Sidus Fortis VPX Commercial Launch in 2027 Backed by $158.5M Funding
Sidus Space announces the commercial availability of its Fortis VPX edge computing module by early 2027, supported by $158.5M raised in Q2 2025. Learn about its technology advantages, market outlook, and financial health.
TOMI Reaffirms 2026 Revenue Guidance of at Least $12M, Sets $10M Funding Goal for Carbonium Core Merger
TOMI Environmental Solutions reaffirms its 2026 revenue guidance of at least $12 million and advances its merger with Carbonium Core, targeting $10 million in funding. This article analyzes the strategic implications, industry context, and potential risks.
